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InflammationAn Adverse Outcome Pathway (AOP) is a conceptual construct that describes existing knowledge on the
link between a molecular initiating event and an adverse outcome. A sequential chain of causally related
events is portrayed at different levels of biological organisation. AOPs are considered to be useful mech-
anistic blueprints for the development of novel tools for human and environmental risk assessment.
Following OECD guidance, an increasing number of AOPs for chemically-induced adverse effects in
humans and environmental species are being proposed. Due to their unique properties, the toxicity of
nanomaterials (NMs) and chemicals is often difficult to directly compare since their mechanisms usually
differ. While there are still many knowledge gaps in our understanding of NM toxicity, an ever increasing
number of mechanistic studies are shedding light on their toxicokinetic and toxicodynamic properties. In
this paper, we introduce the concept of AOPs and analyse its possible implementation for nanotoxicology.
We illustrate how the AOP framework can be used to rationally combine mechanistic knowledge relating
to both NM- and chemically-induced liver toxicity to fill information gaps and guide the development of
toxicity testing strategies. The differences between NM and chemically-induced adversity are proposed to
be primarily related to differences in toxicokinetics and the nature of the initial Key Events in the AOP.
Consequently, much of the mechanistic knowledge captured by AOPs that have been developed from con-
sideration of chemically-induced toxicity is also relevant to describe AOPs applicable to NMs, at least in
qualitative terms, and thus can be used to inform predictive modelling and risk assessment of NM toxicity.
 2016 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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For the regulatory assessment of chemicals, in vivo testing is
still used extensively to fulfil information requirements, even
though animal tests are typically very time-consuming, costly
and questionable from an ethical perspective. Moreover, standard
guideline tests offer sparse information on the mechanism of tox-
icity of a substance and thus provide little help in explaining why a
substance might cause an adverse effect of regulatory concern.
More than a decade ago, recommendations already emerged to
focus on intelligent testing strategies [1] that move away from a
‘‘generalized, checklist approach” to cover data gaps by acquiring
only essential information [2]. This has led to the development of
Integrated Testing Strategies (ITS) to support the implementation
of legislation such as REACH (Registration, Evaluation, Authorisa-
tion and Restriction of Chemicals) in the European Union [3,4],
and to more recent efforts within the Organisation for Economic
Co-operation and Development (OECD) to develop Integrated
Approaches to Testing and Assessment (IATA) which optimally
combine and exploit existing information, in vitro assay data and
computational predictions to satisfy specific information require-
ments [5].
The International Programme on Chemical Safety (IPCS) of the
World Health Organization (WHO) and the International Life
Sciences Risk Sciences Institute (ILSI-RSI) initiated the Mode of
Action (MoA) human relevance framework [6] for a better evalua-
tion and harmonisation of the assessment of chemical risks. Fol-
lowing this, in 2012, a programme for the development of
Adverse Outcome Pathways (AOPs) was launched by the OECD
which has taken up many of the aspects of the WHO/IPCS work
on MoA [7]. Initially described in the context of ecotoxicological
risk assessment, an AOP was defined as ‘‘a conceptual construct
that portrays existing knowledge concerning the linkage between
a direct molecular initiating event (MIE) and an adverse outcome
(AO)”, by capturing the sequential chain of causally-linked Key
Events (KEs) at different levels of biological organisation [8]. Sub-
sequently, the AOP concept was extended to support the assess-
ment of human health effects. AOPs aim to support regulatoryFig. 1. Exemplary flow scheme of a typical AOP, starting from the molecular initiati
Relationships (KERs, red arrows) and resulting in a single specific Adverse Outcome (AO
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development of novel test methods and (OECD) Test Guidelines,
QSAR tools and IATA.
In practical terms, the description of an AOP is highly structured
and follows well-defined principles and conventions, as described
in OECD guidance, a supplementary ‘User handbook’ [9], and in
the scientific literature [10–12]. For example, KEs have to be both
measurable and essential (but not necessarily sufficient) for the AO
in question, and the evidence presented to support the causal link-
ages between individual KEs, termed Key Event Relationships
(KERs), should be based on both biological plausibility and empir-
ical data. Evidence can be derived from various sources including
in vivo and in vitro studies, or from computational modelling [8].
An AO can be defined at various levels: for human health effects,
an AO seldom relates to whole population level, but rather to indi-
vidual organ damage (e.g. liver fibrosis), which has consequences
on the individual, whereas in environmental toxicology the AO
usually relates to growth inhibition, reduced survival or reproduc-
tive impairment of an individual (e.g. a fish) and the consequences
on the whole population. The MIE describes the interaction of a
material (e.g. chemical) with a biological target, and can be either
specific, such as ligand–receptor interaction, or non-specific (e.g. a
toxicant physically residing in a bio-membrane) [9]. By definition,
an AOP consists of a single MIE and a single AO, but can have mul-
tiple causally-linked KEs (Fig. 1). This leads to a simplified and ‘‘lin-
ear” representation of an individual AOP, which may be an
adequate basis for prediction in certain cases. However, since KEs
can be shared by different AOPs, and one MIE can lead to multiple
AOs and vice versa, AOP networks generally represent a more rel-
evant basis for toxicity prediction [12]. To facilitate the develop-
ment of AOPs within a network context and to provide a
practical collaborative platform for AOP developers to systemati-
cally capture, share and integrate their AOP knowledge, the AOP
Knowledge Base, including the AOP-Wiki, has been launched in
2014 as publicly accessible tool [13].
Building of networks can be further supported by the emerging
concept of Aggregate Exposure Pathways (AEPs), which has been
recently introduced to integrate also complex exposure scenariosng event (MIE), inducing a variety of Key Events (KEs) connected by Key Event
).
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framework as so far, AOPs primarily focus on direct relationships
between a toxicity endpoint resulting from the exposure to the
trigger alone. In reality, human exposures are likely to occur as
low dose co-exposures with a wide variety of materials, including
bacterial agents, chemicals and pharmaceuticals. It is reasonable to
suspect that toxicity, especially in the liver, may be driven by sus-
ceptibilities associated with such co-exposures.
To date, AOPs have been developed for chemically-induced AOs,
although there is increasing awareness of this concept also in the
nanotoxicology community. Recently, Vietti and colleagues pub-
lished an overview of current knowledge and gaps on KEs involved
in lung fibrosis development by carbon nanotubes (CNTs), with the
intention to draft a respective AOP [15]. A large variety of KEs was
described based exclusively on CNT-specific literature, leading to a
complex pathway showing the various possibilities of CNT-
induced lung fibrosis. Likewise, Labib and colleagues demonstrated
the development of an AOP relevant for multi-walled carbon
nanotubes (MWCNTs) based on in vivo-derived transcriptomic
data. This exercise led to a simplified and linear AOP, as foreseen
in the AOP guidelines, and demonstrates how transciptomic data
can be used to derive pathway-based points of departure [16].
Again, however, this work is based solely on the literature on
MWCNTs. In the present manuscript, we demonstrate how the
AOP approach can be applied for nanotoxicology utilising not
only NM-specific literature, but also existing knowledge on
chemically-induced mechanistic toxicological processes. Following
the initiator-agnostic AOP-philosophy, we show how the AOP
approach can be used to describe the pathogenesis of NM-
induced health effects of regulatory concern where NM-specific
information is lacking. However, attention needs to be paid to dis-
tinguish NM-specific Key Events from generic ones. The case of
liver toxicity induced by chemicals or metal oxide NMs is used as
an illustration.
2. Toxicity mechanisms of metal oxide nanomaterials
The possible adverse effects of NMs on the human body are
increasingly being discussed and investigated. In 2011, the Euro-
pean Commission proposed to define a NM as ‘‘a natural, incidental
or manufactured material containing particles, in an unbound state
or as an aggregate or as an agglomerate and where, for 50% or more
of the particles in the number size distribution, one or more exter-
nal dimensions is in the size range 1 nm–100 nm” [17]. However,
this definition is under continuous discussion [18]. As the use and
possible application areas of NMs for food and food-related prod-
ucts are increasing, it is not possible to test their toxicity on a case
by case basis [19–22]. To tackle this, the ITS-NANO project has pro-
posed an Intelligent Testing Strategy for NMs, similar to chemical
testing. This strategy will help to identify priority research areas,
ultimately limiting individual NM testing and supporting NM risk
assessment [23,24]. The ITS-NANO report already acknowledged
the usefulness of AOPs as a contributor to an ITS for NMs, and first
AOP concepts, based on particle-specific literature and describing
the species-specific outcomes of sustained particle overload in
the lungs, have been described in an ECETOC technical report in
2013 [25] and by Morfeld and colleagues in 2015 [26].
Some of the major contributors to regular (nano)particle expo-
sure are TiO2 or amorphous SiO2, all commonly used in cosmetics,
pharmaceutical products or foods [20,22]. TiO2 in its usual
micron-size (inert) form is used as a whitener (E171), and also
the synthetic amorphous SiO2 (SAS) is accepted as a common food
additive (E551), mainly in its micron-sized form, and used for
example as an anticaking agent or thickener. A recent approach
to estimate the content of nano-sized SiO2 in food containingPlease cite this article in press as: K. Gerloff et al., The Adverse Outcome Pathw
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124 mg nano-SiO2 per person per day [22], meaning that there
might be continuous exposure and possible bioaccumulation.
Peters and co-workers analysed the amounts of nano-sized SiO2
in several of these E551 containing food products throughout a
simulated gastro-intestinal digestion process. They report a disap-
pearance of nano-sized particles in gastric pH conditions followed
by their pronounced re-formation in an intestinal medium [27]. A
recent approach to translate knowledge on SAS in food into risk
assessment reported low gastrointestinal absorption rates of only
0.03, 0.06 and 0.2%, respectively, depending on the tested material
and the treatment duration or reported study [28]. Interestingly,
the absorption rate seems to decrease with an increase in adminis-
tered SAS concentration, which was explained by possible gelation
of this material in higher concentrations. This highlights once again
that already low doses might result in accumulation and poten-
tially in an adverse effect, since the uptake rate cannot necessarily
be correlated to the administered dose. It also emphasises the
necessity of appropriate kinetic models to accurately predict
uptake rates [28,29].
The ability of NMs to directly induce the formation of reactive
oxygen species (ROS) [19,30,31] is one of the most significant rea-
sons for adverse NM effects. Likewise, oxidative stress is a known
contributor to chemically-induced cell damage and toxicity [32].
A good correlation between cell free and cell-based in vitro ROS for-
mation by NMs with their in vivo inflammation-generating potency
has been described [33]. Low amounts of ROS can activate various
signalling cascades within the cell, such as the phosphoinositide 30-
kinase/protein kinase B pathway which regulates cellular survival
[34]. Excessive ROS formation however can induce genotoxicity,
leading to DNA strand breakage, oxidative lesions, micronucleus
formation or sister chromatid exchanges, and thus can be poten-
tially carcinogenic [35].
In line with this, a classification model was developed to asso-
ciate the reactivity of metal oxide NMs with the potential to gener-
ate oxidative stress [36]. The model is based on the ability of the
NMs to exchange electrons with biological redox species in the cell
(e.g. antioxidant molecules such as cytochrome C and glutathione).
By using this simplified framework, it is possible to predict in a first
ranking whether a given metal oxide has the potential to cause
oxidative stress by checking whether its band energy levels
(conduction and valence bands) overlap with the range of redox
potentials of biological reactions occurring inside the cell. The
model has been verified by independent experimental studies on
24 metal oxide NMs [37]. It should be kept in mind, however, that
this model was only partially accurate in predicting the capacity of
metal oxide NMs to induce oxidative stress, whereas other metal
oxides induce similar effects through ion dissolution. This illus-
trates the importance of relating QSAR properties to proposed
MIEs.
ROS formation is also an important player in the relationship
between inflammation and carcinogenesis. The inflammatory
phagocyte respiratory burst leads to the indirect formation of
ROS, catalysed by nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase [38]. Indeed, activated neutrophils have been
shown to cause oxidative DNA damage in rat lung epithelial cells
[39,40]. Also macrophages are known to play a significant role in
NM induced inflammatory processes. They are a key player in
the uptake and elimination of inhaled NMs [41]. Upon the uptake
of a NP by immune cells such as dendritic cells or macrophages,
the NLRP-3 (NOD-like receptor family, pyrin domain containing
3) inflammasome can be activated. This process that has been
described for both crystalline and amorphous SiO2, but also for
TiO2 and can ultimately lead to oxidative stress, cell death and
inflammation [42,43].ay approach in nanotoxicology, Comput. Toxicol. (2016), http://dx.doi.org/
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uptake for NM-induced toxicity. Once the material is taken up by
a cell (such as macrophages or also human astrocytoma cells)
and transported to the lysosome by autophagy, the acidic milieu
therein can either enhance solubility of a NM, or the material
remains in its initial nano-form. Both situations can induce toxic-
ity, causing lysosomal swelling, followed by lysosomal disruption
and the release of pro-apoptotic proteins and inflammation [44–
46]. It is known that particles of low solubility and toxicity, such
as TiO2, may cause inflammation in proportion to their specific sur-
face area [47,48] and, as more recently described, their zeta poten-
tial [46]. The zeta potential describes the electric potential
between the surface of a NM (or associated groups thereon) and
the suspension medium. It is known that the negatively charged
cell membranes can interact more easily with positively charged
NMs, making these potentially more toxic than neutral or nega-
tively charged NMs [46]. Acute pulmonary inflammogenicity
in vivo is highly correlated with the zeta potential in an acidic envi-
ronment (as present in the lysosomes of a cell) for low-solubility
NMs. Disruption of the lysosome can trigger an inflammation cas-
cade in the target organ. The particle-driven inflammatory
response is associated with tissue damage, remodelling and muta-
genesis and is referred to as secondary particle toxicity following
the exhaustion of antioxidant and DNA damage repair capacities,
as has been described for the lung [30,35,49]. For highly soluble
particles, however, the nature of the ion defines its toxic and/or
inflammogenic potential (e.g. Zn2+ as an example of a highly toxic
ion versus Mg2+ as an example of a low-toxicity ion) [46]. Thus it is
obvious that solubility is an important aspect in nanotoxicology,
and the question arises whether a dissolved material still acts as
a ‘‘nanomaterial” in the target tissue. Therefore, here we focus on
low-solubility NMs.
Once in a matrix (e.g. a food) or dispersed in biological fluids,
such as mucins or the blood plasma, NMs come in contact with a
large variety of proteins (e.g. approx. 3700 in the blood plasma),
leading to the formation of a protein corona. This is the biomole-
cule coating that forms around NMs upon contact with biological
molecules and depends on both the size and surface properties of
the NM [50]. The corona consists of a hard and a soft corona: the
hard corona is a tightly bound, near-monolayer of biomolecules
around the NM, surrounded by a loose layer of biomolecules, the
soft corona. The soft corona can easily be exchanged, whereas
the hard corona often retains biomolecules from previous environ-
ments [51]. Therefore, its composition varies in time and depends
on the environmental conditions [52]. The corona is stable for a
longer time than the typical time scale of cellular uptake, thus act-
ing as cell ‘‘mediator” in the interaction of the NM with cell recep-
tors [53].
2.1. NM-induced liver toxicity
The liver is one of the main target organs for ingested NMs, but
inhaled particles can also reach the liver upon clearance from the
lung [54–57]. The mononuclear phagocyte system, also called
reticuloendothelial system, is one of the important players in NM
uptake and systemic distribution. It consists of the phagocytic
monocytes and macrophages which are present in the body, espe-
cially in the liver but also in spleen, lymph nodes and bone mar-
row. Following recognition and phagocytosis by macrophages of
both the mononuclear phagocyte system organs and in the blood,
NMs are sequestered to those organs. NMs that are taken up by
hepatocytes are potentially excreted into the bile, whereas NMs
phagocytosed by Kupffer cells, the resident macrophages of the
liver, generally remain in the cells for a long period of time if they
can’t be degraded intracellularly [58–61]. Once in the liver, TiO2
nanoparticles may have the potential to induce DNA damage andPlease cite this article in press as: K. Gerloff et al., The Adverse Outcome Pathw
10.1016/j.comtox.2016.07.001mutagenesis [62,63], but this has been described mainly at high
doses and not following inhalation and has been suggested to be
due to induction of systemic inflammation [62]. In vivo experi-
ments on gavaged or injected (intraperitoneal or intravenously)
TiO2 suggest a wide range of adverse effects on the liver: an
increase in general serummarkers for liver damage such as Alanine
Aminotransferase or Aspartate Aminotransferase [64,65], an
increase in inflammatory markers such as pro-inflammatory
cytokines and/or infiltration of inflammatory cells [55,66,67], an
increase of markers for oxidative stress [68,69], apoptosis, necrosis
and also fibrosis [70,71]. It has to be noted, however, that many of
these studies use relatively high particle doses, and the reported
effects are usually seen at the highest treatment doses. When
low doses of NMs induced an adverse effect, such as an influx of
inflammatory cells, recovery to control levels on cessation of NM
exposure was reported [67].
Liver damage and inflammation have also been reported for
other metal oxide particles such as SiO2 [29,72,73] via various
application routes such as intraperitoneal injection or oral admin-
istration. Similarly, increased accumulation of the NMs in the liver
is often reported. Oral NM administration appeared to induce over-
all milder adverse effects than systemic administration, most likely
due to the typically limited absorption of NMs in the GI tract.3. Considerations for the development of AOPs for
nanomaterials
As for most risk assessment approaches, the lack of human data
is a major difficulty in evaluating the human liver toxicity potential
of metal oxide NMs. Risk assessment is based on data from animal
studies, mainly conducted in mice and rats, and from in vitro
experiments with human or rodent cell lines. Moreover, the prop-
erties of the nanomaterials tested in various studies vary greatly.
The most apparent differences lie within the primary particle size
distribution of the materials. NMs of an average primary particle
size of 5 nm may lead to a different AO or altered severity of the
AO than materials of 100 nm size on average. Furthermore, the
tested NMs can vary in their crystalline structure (such as rutile
versus anatase in the case of TiO2) and the ratio of these crystalline
forms, their surface charge, shape or specific surface area. The tox-
icokinetics of the NM, including its solubility, is obviously a key
factor in describing a material’s toxicity, but are often unknown
or only partially described. Another major issue is the lack of suf-
ficient physicochemical characterisation especially in early publi-
cations. The problem and its consequences have been described
extensively [74] and has led to an increased awareness of research-
ers [75,76]. Scientific journals imposed minimal requirements for
adequate NM characterisation and an internationally recognised
guidance has been published by OECD [77]. But even if NMs are
well-described in their pristine form many publications still lack
a thorough characterisation in situ, i.e. the biological fluids the
NM interacts with. Furthermore, tested doses in different studies
can differ immensely and are therefore not comparable; some-
times the high concentrations used are not relevant for real life
exposure conditions. Further, exposure scenarios vary in terms of
duration (days versus weeks or months), the route of exposure
(for example oral gavage vs injection), and the investigated toxico-
logical endpoint.
Understanding the relevant physico-chemical properties of
NMs in biological systems is vital when it comes to defining the
characteristics of the NM that initiates an event which could
potentially result in an AO. Knowledge about the initial fate and
biotransformation of the NM in vivo prior to reaching the biological
target is often sparse, although the route of uptake plays a major
role. Ingested NMs pass through different pH environments prioray approach in nanotoxicology, Comput. Toxicol. (2016), http://dx.doi.org/
K. Gerloff et al. / Computational Toxicology xxx (2016) xxx–xxx 5to their intestinal uptake, affecting the net surface charge [78] and
solubility. The physicochemical properties of the NM and its trans-
formation products have a considerable influence on the absorp-
tion, distribution and excretion processes that ultimately
determine the fate of the NM in the body. Moreover, a NM might
not only act directly at its target organ, but might also cause toxi-
city via second messengers. E.g. inhaled particles are shown to
increase the risk of cardiovascular disease indirectly via the induc-
tion of a pulmonary acute phase response and enhancing
atherosclerotic changes. However, no or only low hepatic acute
phase response could be found following inhalation or instillation
[79].
Information on both toxicokinetics and toxicodynamics needs
to be combined for hazard and risk assessment purposes. By defi-
nition [9], an AOP is limited to the description of toxicodynamics,
but the kinetics can influence the occurrence of the initiating
event.
Another issue in using the AOP framework to describe NM tox-
icity is the nature of the MIE. It is plausible, and probably likely,
that not all interactions of NMs with cells or cellular components
involve a specific molecular interaction or reaction as seen for
many chemicals (e.g. pharmaceuticals or pesticides). NMs could
in fact induce mechanical/physical damage, e.g. to the cell mem-
brane or to the lysosome, which would not be best described as
a ‘‘Molecular” Initiating Event. However, AOP principles and guid-
ance make provision for describing non-specific interactions with a
biological target [9] and for describing an AOP with unknown MIE.
Therefore, when describing NM-relevant AOPs, it is probably often
more appropriate to assign the first KE as initiating event for the
respective AOP that could be termed the initial KE.
A large body of knowledge on NM-induced toxicity and under-
lying mechanisms exists but for the most part this is fragmented
and dispersed across the literature. Different NMs can exhibit tox-
icity through different mechanisms, but at least qualitatively com-
mon mechanisms are shared by many NMs. In fact, there is also
evidence for the comparable toxicological behaviour of nano- and
bulk particles [80]. Developing an AOP is about looking across dif-
ferent material-specific studies and extracting relevant informa-
tion, reduced and discretised into a series of causally linked KEs,
that is applicable to any NM that has the potential to trigger the
(M)IE or initial KE. Restricting this knowledge mining and curation
exercise to NM-specific literature makes knowledge gaps evident.
Considering that downstream toxicological processes are biology-
related rather than substance-specific, the huge chemical-based
mechanistic knowledge base can be used to elucidate toxicological
processes of NMs. Major differences lie in the initial events that
reflect how the chemical or NM perturb the biological system.
Using liver toxicity as a case study, we describe how evidence onFig. 2. AOP ‘‘The Adverse Outcome Pathways from protein alkylation to liver fibrosis”.
Adverse Outcome Pathways from Protein Alkylation to Liver Fibrosis”. It illustrates a goo
narrowing the representation down to the most essential and measureable events.
Please cite this article in press as: K. Gerloff et al., The Adverse Outcome Pathw
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NM-induced adverse effects.
4. Development of a liver-specific AOP applicable to NMs
A number of AOPs for adverse liver outcomes are being elabo-
rated within the OECD AOP development programme [13]. These
AOPs are based on MIEs that are induced by chemicals, but never-
theless their value for developing NM-specific AOPs should not be
underestimated. As described in Section 3, NM-induced (M)IEs
might differ from chemically-induced ones, as in specific cases
they are caused by physical damage rather than molecular interac-
tions. However, certain chemicals can also induce similar (M)IEs as
NMs. Moreover, the downstream biological effects are essentially
the same. To demonstrate this, a well-advanced AOP for
(chemically-induced) liver-fibrosis is presented here and used to
describe similarities and differences to mechanisms known for
NM-derived toxicity.
OECD Project 1.14 ‘‘The Adverse Outcome Pathways from Pro-
tein Alkylation to Liver Fibrosis”, AOP number 38 [81] (Fig. 2)
describes the relevant KEs in the development of liver fibrosis in
humans. With chemically-induced protein alkylation being the
MIE, hepatocyte injury/apoptosis is described as the subsequent
KE. This leads to the activation of Kupffer cells, which account for
approximately 15% of the total liver cell population and are
involved in the pathogenesis of chemical- or toxin-induced liver
injury through the release of inflammatory mediators such as
cytokines, chemokines and lysosomal or proteolytic enzymes.
Kupffer cells are a main source of the most important profibrogenic
cytokine in this process, TGF-b1, and this is described as KE-3. KE-4
describes the subsequent activation of hepatic stellate cells, which
ultimately results in progressive collagen accumulation, the onset
of fibrosis. This process is accompanied throughout by oxidative
stress, which further promotes the development of fibrosis. More-
over, the inflammatory response is a continuous driver in the
development of the AO. As a matter of convention, the oxidative
stress and inflammatory responses are therefore not described as
specific KEs in their own right, but are captured in the KERs. The
presented AOP illustrates how a complex biological process can
be simplified and described in a linear manner.
To describe adverse effects of NMs on the liver, we have focused
on metal oxide NMs such as TiO2 or SiO2. A large number of studies
on general hepatotoxicity endpoints (such as inflammation, liver
damage) have been performed in vivo, whereas in vitro studies
have mainly focused on unveiling the underlying mechanisms. This
has led to the development of the AOP ‘‘Lysosomal damage leading
to liver inflammation” under the OECD framework (AOP number
144) [82]. As described in Section 2, insoluble NMs as well as toxicAOP under development in the AOP wiki under the OECD framework titled ‘‘The
d example of the simplification and linearisation of a complex biological process by
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Fig. 3. Putative AOP applicable to metal oxide NMs leading to hepatitis. AOP under development in the AOP wiki under the OECD framework titled ‘‘Lysosomal damage
leading to liver inflammation”. Metal oxide NMs can induce the AO via lysosomal damage as one relevant (M)IE or initial KE, initiated in hepatocytes. The described AOP leads
to hepatitis as the AO, as described in the literature. The formation of ROS can lead to hepatocyte injury/apoptosis induced by mitochondrial damage, ultimately resulting in
the infiltration of inflammatory cells, inducing the AO.
Fig. 4. Merging of the existing chemically-induced fibrosis-AOP and the putative AOP for metal oxide NMs leading to hepatitis. (A) The major differences lie within the (M)IE
and early KEs. A major downstream KE, ‘‘Hepatic Injury, Apoptosis”, is the same for both AOPs (red circle). Also fibrosis induced by NMs has been reported, but the direct links
are not fully described yet (dotted red circle). KEs in the putative AOP for metal oxide NMs such as ROS formation or inflammation are described in the KERs of the fibrosis-
AOP as they continuously occur throughout the whole process and are not listed here separately (dotted green circle), and similarly, Kupffer cell activation has been described
following metal oxide exposure, but is not part of the actual AOP relevant to NMs. A merging of the two AOPs unveils the direct integration and overlap of mechanisms (B).
The black arrows show the described KERs in the AOP for alkylating agent-induced fibrosis, whereas the blue arrows show the proven links in the putative AOP for metal
oxide NM-induced hepatitis; further proof of the specific KEs leading to fibrosis is still lacking. Combined black and blue arrows show the KERs proven for both approaches.
Oxidative stress and inflammation are included here and linked to the various KEs of the fibrosis-AOP for clarity, and both together with Hepatocyte Injury/Apoptosis are the
KEs that directly merge both AOPs. This suggests that incubation with metal oxide NMs is ultimately expected to induce liver fibrosis development via the KEs known for
chemically-induced fibrosis. However, this has not been confirmed experimentally yet.
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K. Gerloff et al. / Computational Toxicology xxx (2016) xxx–xxx 7ions of soluble NMs can trigger an inflammation cascade by disrup-
tion of the lysosomal membrane, which is considered as the initial
KE in the present AOP (Fig. 3). Alternative NM-induced (M)IEs or
initial KEs can also be envisaged; for example direct ROS formation,
leading to the induction of oxidative stress and inflammation in the
target organ. However, the lysosomal damage in hepatocytes is
known to be a relevant starting point for NM-induced toxicity,
and thus we describe it here as the initial KE. Once the lysosome
is damaged, ROS are formed as a consequence and mitochondrial
damage is initiated, both events further amplifying each other, fol-
lowed by hepatocyte apoptosis and the inflammatory cascade
(Fig. 3).
There are several similarities between KEs of the chemically-
induced fibrosis-AOP and NM-induced toxic effects: liver fibrosis
has been described as the AO resulting from repeated treatment
with TiO2 or SiO2 NMs, following administration via oral treatment
[29,83], i.p. [70,73] or i.v. injection [84]. Exposure of Kupffer cells to
SiO2 NMs leads to their activation via inflammasome activation
[85], causing oxidative stress and inflammation [85,86]. Also, the
appearance of collagen fibres around silicotic nodular like lesions
has been described for NMs [73,84]. However, the downstream
KEs leading to fibrosis development, such as TGF-b1 expression
or hepatic stellate cell activation, are still to be investigated for
NMs. Recent findings on renal cells and mouse kidneys describe
an increase of TGF-b expression following nano-TiO2 treatment
[87], further supporting the assumption that excessive exposure
to metal oxide NMs will ultimately lead to liver fibrosis. However,
it is currently not possible to describe a full NM-relevant AOP lead-
ing to liver fibrosis based on NM toxicology literature alone. Since
the development of liver inflammation due to systemic exposure to
metal oxides is a well-documented phenomenon, this led us to
define hepatitis as the AO, which is in fact a known intermediate
event leading to the development of fibrosis (assuming sustained
exposure).
In an attempt to learn from the well-developed chemically-
induced fibrosis AOP and use this knowledge for the nanotoxicol-
ogy domain, the two AOPs were directly compared and merged
(Fig. 4). Fig. 4A displays both AOPs in parallel, which highlights
similarities and differences. As mentioned above in this section,
‘‘Collagen accumulation” and the AO ‘‘Liver fibrosis” have been
described in the literature for NMs, but no direct link to preceding
KEs has been established yet.
Based on the KER descriptions and an earlier version of the
chemically-induced fibrosis-AOP graph [88], which includes oxida-
tive stress and inflammation (black arrows, Fig. 4B), it is possible to
directly link the KEs of the AOP relevant to NM toxicity (blue
arrows) to the existing fibrosis-AOP. The combined black and blue
arrows display KERs common to both AOPs. This merging clearly
shows that there are major overlaps of KEs, and that the main dif-
ferences between these AOPs lie within the (M)IE or initial KE, and
subsequent (early) KEs. It is very likely that TGF-b1 expression and
hepatic stellate cell activation can be identified as KEs following
NM-treatment, leading to liver fibrosis. Based on this assumption,
research strategies to confirm or refute this hypothesis can be
designed. This also implies that it might be more efficient to base
the predictive modelling of NM toxicity on common KEs, rather
than on widely varying and poorly characterised (M)IEs.5. Conclusions
We demonstrate that the mechanistic knowledge captured in
AOPs that have been developed to describe chemically-induced
toxicity can be utilised to fill knowledge gaps related to the toxicity
of poorly soluble NMs. The major differences in the toxicodynam-
ics of NMs and chemicals lie in the initial upstream events, and inPlease cite this article in press as: K. Gerloff et al., The Adverse Outcome Pathw
10.1016/j.comtox.2016.07.001particular the (M)IE, although here also overlaps exist. However,
chemically- and NM-induced toxicological processes share down-
stream events that lead to a particular AO. Of course, NMs and
chemicals differ considerably in their in vivo biokinetics and in fact
this is the primary factor that sets them apart from a toxicological
perspective, at least when considering the current generation of
engineered NMs. Considering only the toxicodynamic processes
that are described in AOPs, apart from the non-specific nature of
NM induced (M)IEs, much of the mechanistic knowledge that is
required to describe AOPs relevant to NM toxicity can be found
in the chemicals domain. Thus, as AOP networks evolve, the mech-
anistic knowledge captured in KEs and KERs can be also used to
inform on downstream events related to NM toxicity, and ulti-
mately for NM hazard assessment. This provides a tool for a more
effective and efficient targeted testing to fill data and knowledge
gaps that clearly remain in nanotoxicology.
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